Candel therapeutics announces release of initial data on can-2409 in a phase 2 clinical trial showing cytotoxic t cell response and disease control in patients with non-small cell lung cancer

Candel to host investor event and webcast at 6:30 am cdt on june 4 needham, mass., may 26, 2022 (globe newswire) -- candel therapeutics, inc. (nasdaq: cadl), a late clinical stage biopharmaceutical company developing novel oncolytic viral immunotherapies, today announced the publication of abstract #9037 at the american society of clinical oncology (asco) annual meeting taking place june 3-7, 2022, in chicago. the abstract summarizes initial data as of january 10, 2022, from candel's open-label phase 2 clinical trial evaluating can-2409 in combination with anti-pd-1 or pd-l1 agents in patients with stage iii/iv non-small cell lung cancer (nsclc) who have had an inadequate response to immune checkpoint inhibitor treatment. the data presented in the poster will include additional data not included in the abstract from a total of 20 patients as of april 20, 2022, including 16 patients from cohort 2. “the achievement of an 87.5 percent disease control rate in patients whose cancer was progressing on anti-pd-1 treatment at enrollment bolsters the evidence of can-2409's potential to induce immunization against cancer neoantigens in both injected tumors and uninjected metastases so that resistance to checkpoint blockade can be overcome,” said paul peter tak, md, phd, fmedsci, president and ceo of candel. “the occurrence of abscopal effects and clinically meaningful and durable activity, supported by significant biomarker responses and prior monotherapy activity data, strengthens our belief that this investigational agent has the potential to improve outcomes for patients with nsclc who are progressing on anti-pd-1 agents.” experimental treatment with can-2409 plus valacyclovir in combination with anti-pd-1 agents appeared to be well tolerated. the most common treatment-related adverse events were transient flu-like symptoms, such as chills, fever and fatigue, with no grade 4 and two grade 3 events reported.
CADL Ratings Summary
CADL Quant Ranking